Literature DB >> 22797155

A novel EGFR mutation in exon 19 showed stable disease after TKI treatment.

Anthonie J van der Wekken, Jos A Stigt, Nils A't Hart.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22797155     DOI： 10.1097/JTO.0b013e31825ccae8

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  4 in total

1.  Case Report: Afatinib Sensitivity in Rare EGFR E746_L747delinsIP Mutated LUAD With Peritoneal Metastases.

Authors:  Lili Zhang; Lu Yang; Binxu Sun; Yixiao Deng; Jie Yang; Dongfang Wu; Fanming Kong
Journal:  Front Oncol       Date:  2022-05-31       Impact factor: 5.738

2.  Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity.

Authors:  Takahiro Yoshizawa; Ken Uchibori; Mitsugu Araki; Shigeyuki Matsumoto; Biao Ma; Ryo Kanada; Yosuke Seto; Tomoko Oh-Hara; Sumie Koike; Ryo Ariyasu; Satoru Kitazono; Hironori Ninomiya; Kengo Takeuchi; Noriko Yanagitani; Satoshi Takagi; Kazuma Kishi; Naoya Fujita; Yasushi Okuno; Makoto Nishio; Ryohei Katayama
Journal:  NPJ Precis Oncol       Date:  2021-04-16

3.  Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M.

Authors:  Yurong Wang; Ruipan Zheng; Peizhu Hu; Ziheng Zhang; Shujing Shen; Xingya Li
Journal:  BMC Cancer       Date:  2021-11-13       Impact factor: 4.430

4.  The Lifted Veil of Uncommon EGFR Mutation p.L747P in Non-Small Cell Lung Cancer: Molecular Feature and Targeting Sensitivity to Tyrosine Kinase Inhibitors.

Authors:  Guangjian Yang; Chengming Liu; Jiaqi Hu; Yang Sun; Peizeng Hu; Liu Liu; Haiyan Xu; Dazhou Li; Weihua Li; Yaning Yang; Nan Sun; Jie He; Yan Wang
Journal:  Front Oncol       Date:  2022-02-11       Impact factor: 6.244
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.